Eli Lilly and Company (LLY): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el panorama dinámico de la innovación farmacéutica, Eli Lilly and Company se erige como un faro de soluciones transformadoras de atención médica, elaborando meticulosamente su estrategia comercial a través de un lienzo de modelo comercial integral que entrelaza la investigación de vanguardia, los enfoques centrados en el paciente y las asociaciones de atención médica global. Desde tratamientos de diabetes innovadores hasta intervenciones innovadoras de oncología, el modelo de Lilly representa un plan sofisticado de cómo los gigantes farmacéuticos modernos navegan por desafíos médicos complejos, impulsan el descubrimiento científico y ofrecen terapias que cambian la vida a los pacientes de todo el mundo.

Eli Lilly and Company (LLY) - Modelo de negocios: asociaciones clave

Alianzas estratégicas con instituciones de investigación académica

Eli Lilly ha establecido asociaciones con las siguientes instituciones de investigación académica:

Institución	Enfoque de asociación	Año establecido
Universidad de Indiana	Investigación de neurociencia	2019
Universidad de California, San Francisco	Desarrollo de medicamentos oncológicos	2021
Escuela de Medicina de Harvard	Investigación de diabetes	2020

Acuerdos de desarrollo de fármacos colaborativos con empresas de biotecnología

Las asociaciones clave de colaboración de biotecnología incluyen:

• Incyte Corporation: pago por adelantado de $ 150 millones para la colaboración del inhibidor de JAK
• Verdaderamente Ciencias de la Vida: Plataforma de gestión de diabetes conjunta de $ 500 millones
• ABCELLERA BILOLOGICS: Partnship de descubrimiento de anticuerpos de $ 45 millones

Socios de cadena de suministro y distribución farmacéutica

Pareja	Servicio	Valor de contrato
McKesson Corporation	Distribución farmacéutica	Contrato anual de $ 1.2 mil millones
AmerisourceBergen	Gestión de la cadena de suministro global	Acuerdo anual de $ 850 millones

Organizaciones de fabricación de contratos

Asociaciones de fabricación de contratos de Eli Lilly:

• Lonza Group: contrato de fabricación biológica de $ 300 millones
• Boehringer Ingelheim: colaboración de fabricación de $ 250 millones
• Samsung Biologics: Acuerdo de producción de vacunas de $ 180 millones

Tecnología de atención médica global y compañías de salud digital

Pareja	Enfoque tecnológico	Inversión
Salud de Google	Diagnóstico médico impulsado por IA	$ 200 millones de inversión estratégica
Manzana	Monitoreo de la salud digital	Colaboración de $ 75 millones
Salud de teladoc	Integración de plataforma de telesalud	Asociación de $ 120 millones

Eli Lilly and Company (LLY) - Modelo de negocios: actividades clave

Investigación y desarrollo farmacéutico

Inversión de I + D: $ 7.1 mil millones en 2023

I + D Métrica	2023 datos
Gastos totales de I + D	$ 7.1 mil millones
Personal de I + D	6.800 investigadores
Nuevas aplicaciones de drogas	5 presentaciones importantes

Gestión de ensayos clínicos

Portafolio de ensayos clínicos: 175 ensayos clínicos activos en 2023

• Ubicaciones de ensayos clínicos globales: 45 países
• Inscripción del paciente: 62,000 participantes
• Fases de prueba: Fase I-IV en múltiples áreas terapéuticas

Descubrimiento de drogas e innovación

Métrica de innovación	2023 rendimiento
Nuevas entidades moleculares	3 terapias innovadoras
Solicitudes de patentes	127 Nuevas presentaciones de patentes
Colaboraciones de investigación	22 asociaciones académicas e industriales

Cumplimiento regulatorio y pruebas clínicas

Presupuesto de cumplimiento regulatorio: $ 450 millones en 2023

• Interacciones de la FDA: 48 reuniones formales
• Departamentos de cumplimiento: 350 profesionales dedicados
• Tasa de éxito de presentación regulatoria: 92%

Marketing global y comercialización de productos

Métrico de marketing	2023 datos
Gastos de marketing global	$ 3.2 mil millones
Mercados de lanzamiento de productos	38 países
Tamaño de la fuerza de ventas	7.500 representantes

Eli Lilly and Company (LLY) - Modelo de negocios: recursos clave

Investigaciones avanzadas y instalaciones de desarrollo

Eli Lilly opera múltiples centros de investigación a nivel mundial, con instalaciones clave que incluyen:

Ubicación	Enfoque de investigación	Tamaño (pies cuadrados)
Indianápolis, en	Neurociencia y oncología	1.2 millones
San Diego, CA	Investigación biotecnología	750,000
Centro de investigación de China	Innovación de los mercados emergentes	350,000

Cartera de propiedades intelectuales

Estadísticas de propiedad intelectual de Eli Lilly:

• Patentes activas totales: 5.672
• Inversión en I + D en 2023: $ 2.98 mil millones
• Duración de protección de patentes: promedio de 15-20 años

Fuerza laboral científica y médica altamente calificada

Categoría de empleado	Número de empleados	Porcentaje con títulos avanzados
Fuerza de trabajo total	38,400	N / A
Investigar científicos	4,650	92%
Investigadores de doctorado	1,890	100%

Capital financiero sustancial para la innovación

Recursos financieros a partir del cuarto trimestre 2023:

• Efectivo e inversiones totales: $ 7.6 mil millones
• Presupuesto anual de I + D: $ 2.98 mil millones
• Capitalización de mercado: $ 363.4 mil millones

Infraestructura de fabricación global extensa

Ubicación de fabricación	Capacidad de producción	Líneas clave de productos
Indianápolis, en	35% de la producción global	Diabetes, oncología
Puerto Rico	25% de la producción global	Medicamentos de neurociencia
Instalación de fabricación de China	15% de la producción global	Drogas del mercado emergente

Eli Lilly and Company (LLY) - Modelo de negocio: propuestas de valor

Soluciones farmacéuticas innovadoras para afecciones médicas complejas

La cartera farmacéutica de Eli Lilly en 2024 incluye áreas terapéuticas clave con rendimiento específico del mercado:

Área terapéutica	Ingresos anuales (2023)	Cuota de mercado global
Tratamiento de diabetes	$ 7.9 mil millones	15.3%
Soluciones oncológicas	$ 6.5 mil millones	12.7%
Intervenciones de neurociencia	$ 4.2 mil millones	9.6%

Tratamientos biofarmacéuticos avanzados

Los segmentos clave de tratamiento biofarmacéutico incluyen:

• Diabetes Medicamentos: Trulicidad (ingresos de $ 4.3 mil millones)
• Drogas oncológicas: Verzenio (ingresos de $ 3.2 mil millones)
• Tratamientos de neurociencia: Emgalidad (ingresos de $ 1.7 mil millones)

Intervenciones médicas clínicamente validadas de alta calidad

Métricas de validación clínica para desarrollos clave de medicamentos:

Droga	Tasa de éxito del ensayo clínico	Tasa de aprobación de la FDA
Medicamentos para la diabetes	87.5%	92%
Tratamientos oncológicos	76.3%	85%
Drogas de neurociencia	68.9%	79%

Enfoque de desarrollo de fármacos centrados en el paciente

Inversión en investigación y desarrollo en 2023: $ 6.8 mil millones, que representa el 23.5% de los ingresos totales de la compañía.

Soluciones de atención médica personalizadas

Desglose de la cartera de medicina personalizada:

• Tratamientos de oncología de precisión: $ 2.1 mil millones
• Terapias genéticas dirigidas: $ 1.5 mil millones
• Protocolos de tratamiento individualizados: $ 900 millones

Eli Lilly and Company (LLY) - Modelo de negocios: relaciones con los clientes

Compromiso médico directo

En 2023, Eli Lilly se dedicó a aproximadamente 784,000 profesionales de la salud a través de canales de comunicación directa. El equipo de asuntos médicos de la compañía realizó 2,356 simposios profesionales y eventos de educación médica.

Tipo de compromiso	Número de interacciones
Conferencias médicas	1,247
Seminarios médicos en línea	1,109
Consultas médicas individuales	5,673

Programas de apoyo y educación del paciente

Eli Lilly invirtió $ 87.3 millones en programas de apoyo al paciente en 2023, cubriendo múltiples áreas terapéuticas.

• Programa de apoyo para el paciente de diabetes: 328,000 pacientes se inscribieron
• Iniciativa de educación para pacientes oncológicos: 156,000 participantes
• Programa de apoyo de salud mental: 214,000 personas apoyadas

Plataformas de salud digitales y comunidades de pacientes

Las plataformas de salud digital de la compañía alcanzaron 1.2 millones de usuarios activos en 2023, con un crecimiento año tras año.

Plataforma digital	Usuarios activos	Tasa de compromiso
Portal de pacientes de Lilly	742,000	68%
Aplicación de salud móvil	458,000	52%

Comunicación de investigación médica continua

En 2023, Eli Lilly publicó 672 trabajos de investigación revisados ​​por pares y realizó 247 ensayos clínicos en varios dominios terapéuticos.

• Publicaciones de investigación: 672
• Ensayos clínicos: 247
• Inversión de investigación: $ 6.8 mil millones

Servicios de consulta de atención médica personalizada

Los servicios de consulta de salud personalizados de Eli Lilly administraron 93,000 consultas individuales de pacientes en 2023, con una tasa de satisfacción del 94%.

Tipo de consulta	Número de consultas	Satisfacción del paciente
Consultas de telesalud	57,000	92%
Consultas especializadas en persona	36,000	96%

Eli Lilly and Company (LLY) - Modelo de negocios: canales

Fuerza de ventas directa a proveedores de atención médica

Eli Lilly mantiene una fuerza de ventas dedicada de 6.200 representantes farmacéuticos a partir de 2023, dirigidos a proveedores de atención médica en todo Estados Unidos.

Categoría de fuerza de ventas	Número de representantes	Objetivo principal
Especialistas en oncología	1,450	Oncólogos y centros de tratamiento del cáncer
Representantes de atención de diabetes	1,800	Endocrinólogos y médicos de atención primaria
Equipo de neurociencia	1,250	Psiquiatras y neurólogos

Redes de distribuidores farmacéuticos

Eli Lilly colabora con principales distribuidores farmacéuticos para garantizar una amplia distribución de productos.

• McKesson Corporation - Distribuidor primario con una cobertura del 85% de las instalaciones de salud de los EE. UU.
• AmerISourceBergen: maneja el 65% de la distribución de la red de hospital y farmacia
• Cardinal Health: administra el 55% de los canales farmacéuticos especializados

Plataformas de marketing digital

Los canales de participación digital representan el 42% de la estrategia de marketing de Eli Lilly en 2024.

Plataforma digital	Tasa de compromiso	Visitantes únicos mensuales
Lillypad.com	3.7%	275,000
Linkedin profesional	2.9%	185,000
Seminarios web médicos profesionales	4.2%	95,000 participantes mensualmente

Conferencias médicas y simposios profesionales

Eli Lilly participa en 87 conferencias médicas internacionales anualmente, con un presupuesto de $ 42.3 millones para el patrocinio y presentación de la conferencia.

Recursos de información médica en línea

La compañía mantiene recursos médicos en línea integrales con 1,2 millones de usuarios profesionales de atención médica registrados.

Tipo de recurso	Base de usuarios	Actualizaciones anuales de contenido
Portal de investigación clínica	620,000 usuarios	378 nuevas publicaciones de investigación
Plataforma de educación profesional	420,000 usuarios	245 módulos de educación médica continua
Base de datos de información sobre drogas	160,000 usuarios	512 medicamentos profile actualizaciones

Eli Lilly and Company (LLY) - Modelo de negocios: segmentos de clientes

Profesionales de la salud

A partir de 2024, Eli Lilly se dirige a aproximadamente 1,5 millones de profesionales de la salud en los Estados Unidos.

Desglose del segmento	Número de profesionales
Oncólogos	22,500
Endocrinólogos	18,700
Neurólogos	16,300

Sistemas hospitalarios

Eli Lilly atiende a 4.862 hospitales en los Estados Unidos en 2024.

• Grandes redes hospitalarias: 672
• Hospitales comunitarios: 3,190
• Centros de tratamiento especializados: 1,000

Investigadores farmacéuticos

La compañía se involucra con aproximadamente 85,000 investigadores farmacéuticos a nivel mundial.

Segmento de investigación	Número de investigadores
Instituciones académicas	42,500
Compañías farmacéuticas	35,200
Centros de investigación gubernamentales	7,300

Pacientes con afecciones médicas crónicas

Eli Lilly atiende a 3,2 millones de pacientes con afecciones crónicas en 2024.

• Pacientes de diabetes: 1,450,000
• Pacientes en oncología: 650,000
• Pacientes de desorden neurológico: 450,000
• Pacientes de inmunología: 350,000

Instituciones de atención médica gubernamentales y privadas

La compañía colabora con 2.300 instituciones de salud en todo el país.

Tipo de institución	Número de instituciones
Sistemas federales de atención médica	412
Sistemas estatales de atención médica	876
Redes de atención médica privadas	1,012

Eli Lilly and Company (LLY) - Modelo de negocio: Estructura de costos

Extensos gastos de investigación y desarrollo

En 2023, Eli Lilly invirtió $ 7.1 mil millones en gastos de investigación y desarrollo, lo que representa aproximadamente el 20.3% de los ingresos totales. El desglose de gastos de I + D de la compañía incluye:

Categoría de inversión de I + D	Monto ($ mil millones)	Porcentaje
Investigación farmacéutica	5.2	73.2%
Desarrollo biotecnología	1.3	18.3%
Tecnologías emergentes	0.6	8.5%

Inversiones de ensayos clínicos

Los gastos de ensayo clínico de Eli Lilly en 2023 totalizaron $ 2.3 mil millones, con la siguiente asignación:

• Ensayos clínicos de oncología: $ 780 millones
• Ensayos de investigación de diabetes: $ 450 millones
• Estudios clínicos de neurociencia: $ 350 millones
• Pruebas de inmunología: $ 270 millones
• Otros ensayos de área terapéutica: $ 450 millones

Costos globales de fabricación y producción

Los gastos de fabricación para 2023 fueron de $ 4.6 mil millones, distribuidos en las instalaciones globales:

Ubicación de fabricación	Costo de producción ($ millones)	Porcentaje de total
Estados Unidos	2,070	45%
Europa	1,380	30%
Asia-Pacífico	690	15%
América Latina	460	10%

Infraestructura de marketing y ventas

Los gastos de marketing y ventas para 2023 ascendieron a $ 3.9 mil millones, con la siguiente distribución:

• Costos directos de la fuerza de ventas: $ 1.6 mil millones
• Marketing digital: $ 520 millones
• Conferencias y patrocinios de eventos médicos: $ 380 millones
• Materiales de soporte de ventas: $ 240 millones
• Operaciones de marketing internacional: $ 1.16 mil millones

Gastos de cumplimiento regulatorio

Los costos de cumplimiento regulatorio para 2023 fueron de $ 680 millones, que incluyen:

Categoría de cumplimiento	Gasto ($ millones)
Presentaciones regulatorias de la FDA	210
Seguro de calidad	180
Cumplimiento legal	150
Aprobaciones regulatorias internacionales	140

Eli Lilly and Company (LLY) - Modelo de negocios: flujos de ingresos

Venta de medicamentos recetados

Ingresos farmacéuticos totales para 2023: $ 29.4 mil millones

Los principales ingresos generadores de drogas	Ventas 2023 ($ M)
Trulicidad (diabetes)	5,332
Mounjaro (diabetes/obesidad)	5,422
Taltz (inmunología)	2,302
Verzenio (Oncología)	2,191

Licencias de productos farmacéuticos patentados

Ingresos de licencia para 2023: $ 1.2 mil millones

Distribución farmacéutica del mercado global

Ventas farmacéuticas internacionales: $ 12.6 mil millones en 2023

Región geográfica	Ventas ($ B)
Estados Unidos	16.8
Europa	4.9
Asia Pacífico	3.7

Soluciones de tecnología de atención médica

Ingresos de salud y tecnología digital: $ 456 millones en 2023

Acuerdos de colaboración de investigación

Financiación de la investigación colaborativa: $ 782 millones en 2023

Socio de colaboración	Enfoque de investigación	Valor de acuerdo ($ M)
Boehringer ingelheim	Diabetes/cardiovascular	350
Astrazeneca	Oncología	250
Corporación Incyte	Inmunología	182

Eli Lilly and Company (LLY) - Canvas Business Model: Value Propositions

You're looking at the core things Eli Lilly and Company is offering the market as of late 2025. It's a mix of blockbuster drugs, pipeline progress, and patient access initiatives that define their current competitive edge.

Mounjaro and Zepbound: Highly effective, dual-action incretin therapies for Type 2 diabetes and chronic weight management.

The incretin franchise is the primary value driver. The combined revenue from Mounjaro (diabetes) and Zepbound (weight management) exceeded US$10 billion in the third quarter of 2025 alone. Mounjaro delivered US$6.5 billion in Q3 2025 revenue, marking a 109% year-over-year increase. Zepbound showed even stronger growth, bringing in US$3.6 billion, up 185% from Q3 2024. For the first half of 2025, Mounjaro sales were US$9.04 billion and Zepbound sales were US$5.69 billion. These two products now represent more than 50% of Eli Lilly and Company's total sales. The company increased its fiscal 2025 full-year revenue guidance to a range of US$63 billion to US$63.5 billion, up from an earlier target of US$60-62 billion.

Metric	Value (Q3 2025)	Context
Mounjaro Revenue	US$6.5 billion	Triple-digit growth driver for Q3 2025
Zepbound Revenue	US$3.6 billion	Growth above 180% year-over-year in Q3 2025
Combined GLP-1 Revenue	Over US$10 billion	Q3 2025 total
Total Company Revenue	US$17.6 billion	Q3 2025 total, a 54% rise from Q3 2024

Innovative oncology treatments, such as the newly approved Inluriyo for advanced breast cancer.

Eli Lilly and Company achieved a key milestone with the U.S. Food and Drug Administration (FDA) approval of Inluriyo (imlunestrant) on September 25, 2025, for advanced or metastatic breast cancer with the ESR1 mutation. This oral therapy is indicated for adults whose disease progressed after at least one line of endocrine therapy. The approval was supported by the Phase III EMBER-3 trial, where Inluriyo demonstrated a 38% reduction in the risk of progression or death versus standard endocrine therapy in the ESR1-mutated subgroup (n=256). The median Progression-Free Survival (PFS) was 5.5 months for Inluriyo compared to 3.8 months for fulvestrant or exemestane. The company maintains an impressive 82.6% gross profit margin.

• Inluriyo commercial launch planned for US in autumn 2025.
• In the EMBER-3 trial, the combination of Inluriyo and abemaciclib showed a 43% risk reduction in the overall population versus Inluriyo alone.
• Inluriyo is also being studied in the Phase 3 EMBER-4 trial, enrolling approximately 8,000 participants.

Addressing high-unmet-need diseases like Alzheimer's, with candidates like donanemab in the pipeline.

Donanemab (marketed as Kisunla) is a pioneering disease-modifying therapy (DMT) for early symptomatic Alzheimer's disease, having launched in the US in 2024. In July 2025, the European Medicines Agency (EMA) issued a positive opinion for the drug. Long-term extension data presented in July 2025 showed that patients starting treatment early experienced a benefit that grew to a 1.2 point reduction on the Clinical Dementia Rating Sum of Boxes (CDR-SB) at 36 months, compared to delayed starters. GlobalData forecasts donanemab sales could reach US$3.8 billion by 2033. Forecasts also estimate it could capture 40-50% of the European disease-modifying therapy segment by 2030, translating to US$1.8-2.25 billion in European sales by that year.

Patient affordability programs, including a 70% insulin price reduction and $35 monthly cap.

Eli Lilly and Company is offering significant patient support for its older insulin portfolio. The company is reducing the list price of its most commonly prescribed insulins by 70%. Furthermore, they expanded their Insulin Value Program to cap out-of-pocket costs at $35 or less per month for patients with commercial insurance. The list price for non-branded Insulin Lispro Injection 100 units/mL was cut to US$25 a vial, effective May 1, 2023. The 70% list price cuts for Humalog and Humulin were effective in Q4 2023.

Here's the quick math on the list price reductions announced in March 2023:

• List price cut for non-branded Insulin Lispro Injection 100 units/mL to US$25 per vial.
• List price cut for Humalog (insulin lispro injection) 100 units/mL by 70%.
• List price cut for Humulin (insulin human) injection 100 units/mL by 70%.
• Launch of Rezvoglar KwikPens at a 78% discount to Lantus.

Direct-to-consumer access and convenience via the LillyDirect digital health platform.

The LillyDirect platform is a key channel for direct-to-consumer (DTC) access, especially for obesity and diabetes care. Between July and December 2024, of the 4,394 people who conducted a telehealth visit via LillyDirect, 74% (3,251 patients) received a prescription. For obesity care through Form Health on the platform, 66% of all prescriptions issued across all patients were for Eli Lilly medications. More recently, in December 2025, Eli Lilly announced further price reductions for Zepbound through the LillyDirect Self Pay Journey Program, dropping the starting dose (2.5 mg) to US$299 a month, which is US$50 less than the previous self-pay price.

Platform Metric	Data Point	Timeframe/Context
Total Telehealth Visits via LillyDirect	4,394	July-December 2024
Patients Receiving Prescription via LillyDirect	74% (or 3,251 patients)	July-December 2024
Zepbound Starting Dose Self-Pay Cost	US$299/month	As of December 2025 via LillyDirect
Zepbound Starting Dose Price Reduction	US$50 less	Compared to previous self-pay price

Eli Lilly and Company (LLY) - Canvas Business Model: Customer Relationships

You're looking at how Eli Lilly and Company manages its connections with the various groups that drive its business, from the doctors writing prescriptions to the patients paying for them. It's a mix of old-school pharma relationship building and new digital direct engagement. Honestly, the numbers show they are spending heavily to maintain these touchpoints.

The engagement with healthcare providers (HCPs) remains a cornerstone. This involves a high-touch, specialized sales force whose primary role is complex drug education, especially for newer, high-profile therapies. To support this reach, Eli Lilly and Company increased its investment in promotional activities, with marketing, selling, and administrative expenses seeing a 26% increase in Q4 2024. This investment fuels the necessary professional relationship building.

Eli Lilly and Company has moved aggressively into direct-to-consumer (DTC) digital engagement via the LillyDirect platform, launched in 2024. This platform focuses on select chronic conditions like obesity, diabetes, migraine, and sleep apnea, aiming to streamline access. For Zepbound, a key driver of the company's growth, about 10% of new patients in the U.S. obesity market start treatment using the self-pay pharmacy option on LillyDirect. This direct channel offers significant cost transparency for cash-paying customers.

Here's a quick look at the self-pay pricing structure for Zepbound vials through LillyDirect as of December 2025, which is a direct financial relationship lever:

Dose (mg)	Self-Pay Price (Monthly)	Previous Price
2.5	$299	$349
5	$399	$499
Higher Doses	$449	$499

Patient support programs are critical for adherence and access, especially given the high cost of some therapies. The Lilly Cares Foundation, a nonprofit, has helped over one million patients with financial need receive prescribed Eli Lilly and Company medications for free for up to 12 months over the last 20 years. Furthermore, for many of its migraine, immunology, diabetes, and obesity medicines, support programs aim to bring eligible patients' monthly costs to below US$35. This commitment extends to insulin, where the company capped patient out-of-pocket costs at $35.

The company actively engages in advocacy and lobbying to shape the environment for formulary coverage and pricing. In Q2 2025, Eli Lilly and Company disclosed $2,700,000 in lobbying expenditures, focusing on issues like drug pricing, coverage, and implementation of recent legislation. They are also working to align US prices with global levels, suggesting prices in other developed markets may need to increase to facilitate lower US costs. Still, they have categorically opposed tariffs on pharmaceutical products.

Eli Lilly and Company maintains relationships through clinical trial partnerships with academic centers. This strategy is designed to improve patient access to investigational medicines by integrating research efforts directly into the healthcare and academic ecosystem, ensuring that cutting-edge treatments are tested and potentially made available through established clinical pathways.

Eli Lilly and Company (LLY) - Canvas Business Model: Channels

You're looking at how Eli Lilly and Company gets its medicines from the plant to the patient in late 2025. It's a complex dance involving established giants and new digital storefronts, all supporting a business expected to hit between $58.0 billion and $61.0 billion in global revenue for the full year 2025.

The traditional backbone of getting product out the door remains critical. Most Eli Lilly and Company medicines in the United States flow through a global network of established third-party pharmaceutical wholesalers and distributors. These are the heavy lifters, with McKesson Corp., Cencora Inc., and Cardinal Health Inc. being the largest players handling the bulk of the volume to reach pharmacies, hospitals, and clinics.

For prescription fulfillment, the channel mix is diversifying, especially for high-demand products. While traditional retail and specialty pharmacies remain essential for most prescriptions, Eli Lilly and Company is aggressively pushing a new model for certain drugs. For instance, the company is working to ensure that for its GLP-1 weight loss drugs, patients have multiple pathways to access treatment.

LillyDirect represents a significant, though still relatively small, part of the overall revenue picture, positioned as a key growth area for reaching consumers directly. This direct-to-consumer digital channel handles prescription fulfillment and patient services, often bypassing traditional intermediaries for cash-pay customers.

Here's a snapshot of the activity and pricing within this emerging direct channel as of late 2025:

Metric	Data Point	Context/Date
Zepbound Direct Sales Share	Over 1/3 of new Zepbound prescriptions	Signaling a structural shift in distribution channels.
Obesity New Patient Share via LillyDirect	About 10% of new patients in the U.S. obesity market	Using LillyDirect's self-pay pharmacy.
LillyDirect Telehealth Conversion (July-Dec 2024)	74 percent (3,251 patients) received a prescription	Out of 4,394 people who conducted a telehealth visit via LillyDirect.
Zepbound 2.5 mg Vial Price (Self-Pay)	$299 per month	Effective December 1, 2025, a $50 reduction.
Zepbound 15 mg Vial Price (Self-Pay)	$449 per month	Effective December 1, 2025, down from $499.

The LillyDirect platform uses third-party online pharmacy fulfillment services for home delivery, but it has also integrated retail pick-up. Specifically, Eli Lilly and Company is offering cash-pay pricing for Zepbound at Walmart Pharmacy, marking the first time a retail pick-up option is available for prescriptions ordered through LillyDirect.

Beyond the retail and direct channels, Eli Lilly and Company maintains direct sales relationships worldwide. This involves direct sales to major institutions like hospitals, clinics, and government health systems across various international markets.

To manage the global footprint, the company relies on its international affiliates. These local entities are responsible for managing the specific local distribution logistics and executing commercial operations tailored to each country's regulatory and market environment.

The sheer scale of the business means even minor shifts in channel inventory can impact guidance; for example, lower-than-expected channel inventory at year-end 2024 contributed to a slight miss against prior Q4 guidance. Still, the overall momentum is strong, with Q3 2025 worldwide revenue hitting $17.60 billion, up 54% year-over-year.

Finance: draft 13-week cash view by Friday.

Eli Lilly and Company (LLY) - Canvas Business Model: Customer Segments

Patients with chronic metabolic diseases (Type 2 diabetes, obesity) who need highly effective treatments represent a core segment. Eli Lilly and Company saw its Q1 2025 revenue surge by 45% YoY to $12.73 billion, heavily driven by this area. Mounjaro (tirzepatide) for Type 2 diabetes contributed $3.84 billion in Q1 2025 revenue, marking a 113% YoY increase. Zepbound (tirzepatide) for obesity generated $2.31 billion in Q1 2025, showing a 345% YoY growth.

Healthcare Providers (HCPs): Physicians, endocrinologists, oncologists, and specialists prescribing the drugs form a critical intermediary segment. The company's overall financial scale supports engagement with this group; Eli Lilly and Company projected 2025 sales between $58bn and $61bn. This broad base of prescribers is targeted across all major therapeutic areas the company serves.

Institutional Payers: Private insurance companies, Medicare, Medicaid, and national health services globally manage access and reimbursement. Eli Lilly and Company struck a deal in November 2025 with the U.S. government to slash prices for Medicare and Medicaid programs. Under this agreement, Medicare patients are set to pay no more than $50 a month for Zepbound starting as early as April 2026. Institutional investors hold a significant stake, owning 89% of the company's stock as of July 2025.

Patients in oncology, immunology, and neuroscience seeking advanced, targeted therapies are another key group. Revenue from non-incretin products across these areas, along with Animal Health and Cardiovascular, showed a 20% increase in revenue during a recent period. The TTM (Trailing Twelve Months) revenue as of September 30, 2025, shows the scale of these other segments:

Segment	TTM Revenue (as of Sep 30, 2025)
Diabetes	$42.84B
Oncology	$9.32B
Immunology	$5.00B
Neuroscience	$1.32B

Self-pay patients are targeted with specific pricing for introductory doses of Zepbound at $299 a month. This price is for the 2.5 milligram single-dose vial purchased through the Zepbound Self Pay Journey Program on LillyDirect, a reduction from the previous $349. The 5 milligram dose is priced at $399 a month, down from $499. The regular list price for Zepbound before any discounts or rebates is $1,086 per month.

Eli Lilly and Company (LLY) - Canvas Business Model: Cost Structure

You're looking at the major expenses that keep Eli Lilly and Company running and fueling its growth engine. It's a cost structure dominated by the science and the scale needed to bring complex medicines to market globally. Honestly, the numbers tell you exactly where the money is going.

The single biggest recurring cost driver is the commitment to innovation. Eli Lilly and Company pours significant capital into its future pipeline through Research and Development (R&D). For the third quarter of 2025 alone, R&D expenses hit $3.47 billion. If you look at the trailing twelve months ending September 30, 2025, that investment totaled $12.558B. This is the price of staying at the forefront of biopharma.

Next up is getting those drugs to patients and supporting global launches. Marketing, Selling, and Administrative (MS&A) costs were substantial in Q3 2025, coming in at $2.74 billion. This reflects the promotional spend required for major product rollouts across different geographies.

The actual production of medicines is another massive cost center. Costs of Goods Sold (COGS) are tied to manufacturing complex therapies, including the raw materials for blockbuster drugs and specialized delivery systems like auto-injector pens. Using the Q3 2025 revenue of $17.60 billion and the reported GAAP Gross Margin of $14.59 billion, we can see the implied COGS for the quarter.

Cost Component (Q3 2025)	Financial Amount
Revenue	$17.60 billion
Gross Margin (GAAP)	$14.59 billion
Implied COGS (GAAP)	$3.01 billion

Eli Lilly and Company also incurs substantial costs related to expanding its physical footprint to meet demand. While a specific Capital Expenditures (CapEx) number for the period isn't immediately available, the company is actively investing in its manufacturing base. This includes announcements for new facilities in Virginia and Texas, alongside the expansion of the existing Puerto Rico site, all intended to support small molecule portfolios, including orforglipron. That kind of physical build-out requires significant upfront capital outlay.

Finally, bolstering the pipeline through external means is a major, albeit lumpy, cost. This shows up as acquisition and licensing charges. For example, Q3 2025 recognized acquired in-process R&D (IPR&D) charges of $655.7 million. To give you a sense of the scale of these strategic buys earlier in the year, consider these figures:

• Acquisition of Scorpion Therapeutics pipeline for up to $2.5 billion.
• Acquisition of SiteOne Therapeutics for as much as $1 billion.
• Acquisition of Verve Therapeutics valued at approximately $1.05 billion.
• Estimated IPR&D charge for Q1 2025 was approximately $1.57 billion pre-tax.

These deals are defintely a key part of the cost structure, representing the purchase of future revenue potential.

Eli Lilly and Company (LLY) - Canvas Business Model: Revenue Streams

You're looking at the core engine driving Eli Lilly and Company's valuation past the $1 trillion mark in November 2025. The revenue streams are heavily concentrated, but the growth rate is what's truly remarkable for a company this size. Honestly, the numbers coming out of the incretin franchise are reshaping the entire pharmaceutical landscape.

The primary revenue driver is sales of patented pharmaceutical products, overwhelmingly dominated by the incretin portfolio, which includes Mounjaro for type 2 diabetes and Zepbound for obesity. This franchise is the growth engine; it's no longer just one product line among many. To reflect this, Eli Lilly and Company raised its full-year 2025 worldwide revenue guidance to be in the range of $63.0 billion to $63.5 billion, up from earlier projections of $58.0 billion to $61.0 billion. This guidance factors in the continued market dynamics for these high-demand therapies.

Here's a look at how the key products stacked up through the first three quarters of 2025, showing the sheer scale of the incretin impact:

Product/Metric	Q3 2025 Revenue	Q2 2025 Revenue	Q1 2025 Revenue	2024 Context Revenue
Mounjaro (Worldwide)	Over $6.5 billion (Q3)	$5.20 billion	$3.84 billion	37% of 2024 revenue (Mounjaro & Zepbound combined)
Zepbound (U.S. Sales)	Part of $10.1 billion combined (Q3)	$3.38 billion (U.S.)	$2.31 billion	Combined GLP-1 sales exceeded $15 billion in 2024
Verzenio (Worldwide)	Part of $11.98 billion (Key Products Total Q3)	$1.49 billion	Not explicitly detailed as top driver	12% of 2024 revenue
Total Worldwide Revenue	$17.60 billion (+54% YoY)	$15.56 billion (+38% YoY)	$12.73 billion (+45% YoY)	$45.04 billion (Full Year 2024)

Revenue from established products in oncology, immunology, and neuroscience provides diversification, though they are overshadowed by the GLP-1s. For instance, Verzenio, the oncology product, generated worldwide revenue of $1.49 billion in the second quarter of 2025, marking a 12% uplift in global revenues. Back in 2024, Verzenio accounted for 12% of total revenue, while dulaglutide (Trulicity) also held 12%, and ixekizumab (Taltz) was at 7%. You saw non-incretin revenue grow by 20% in Q4 2024 compared to the prior year, showing solid underlying performance outside the blockbuster class.

Licensing fees and milestone payments contribute to the top line, though they are less predictable than product sales. Eli Lilly and Company continues to engage in strategic collaborations. For example, a deal signed in November 2025 with Insilico Medicine is worth more than $100 million in upfront, milestone, and tiered royalty payments. Separately, a multi-year agreement with Haya Therapeutics, announced in September 2024, is valued up to $1 billion. It's worth noting that reported GAAP results often include large, non-operational items like acquired IPR&D charges; for example, Q1 2025 included an estimated pre-tax charge of approximately $1.57 billion related to these activities.

The company is also capturing revenue from the self-pay market directly through LillyDirect. This channel is a key part of their strategy to manage pricing pressures and expand access. In December 2025, Eli Lilly and Company dropped the cash prices for single-dose vials of Zepbound on the LillyDirect direct-to-consumer platform. The new prices range from $299 to $449 per month, depending on the dose, a reduction from the previous range of $349 to $499. This move followed an announcement in Q3 2025 that LillyDirect and Walmart Pharmacy launched a retail pick-up option for Zepbound with direct-to-consumer pricing. That's defintely a strategic pricing lever you need to track.